Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients
- 20 April 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (5) , 1229-1237
Abstract
Background: By assessing the spectrum of hematologic malignancies associated with solid-organ transplantation in the elderly, we provide information on the pathogenesis of lymphoid and myeloid neoplasms and the clinical manifestations of immunosuppression. Methods: Using data from the U.S. Surveillance, Epidemiology, and End Results Medicare database, we identified 83,016 cases with a hematologic malignancy (age 66-99 years) and 166,057 population-based controls matched to cases by age, sex, and calendar year. Medicare claims were used to identify a history of solid-organ transplantation. We used polytomous logistic regression to calculate odds ratios (OR) comparing transplantation history among cases with various hematologic malignancy subtypes and controls, adjusting for the matching factors and race. Results: A prior solid-organ transplant was identified in 216 (0.26%) cases and 204 (0.12%) controls. Transplantation was associated with increased risk for non–Hodgkin lymphomas [OR, 2.13; 95% confidence interval (95% CI), 1.67-2.72], especially diffuse large B-cell lymphoma (OR, 3.29; 95% CI, 2.28-4.76), marginal zone lymphoma (OR, 2.48; 95% CI, 1.17-5.22), lymphoplasmacytic lymphoma (OR, 3.32; 95% CI, 1.41-7.81), and T-cell lymphoma (OR, 3.07; 95% CI, 1.56-6.06). Transplantation was also associated with elevated risk of Hodgkin lymphoma (OR, 2.53; 95% CI, 1.01-6.35) and plasma cell neoplasms (OR, 1.91; 95% CI, 1.24-2.93). Risks for myeloid neoplasms were also elevated (OR, 1.99; 95% CI, 1.41-2.81). Conclusion: Solid-organ transplantation is associated with a wide spectrum of hematologic malignancies in the elderly. Risk was increased for four specific non–Hodgkin lymphoma subtypes for which a viral agent has been implicated, supporting an added role for immunosuppression. Impact: Our results support monitoring for a wide spectrum of hematologic malignancies following solid-organ transplant. Cancer Epidemiol Biomarkers Prev; 19(5); 1229–37. ©2010 AACR.Keywords
This publication has 38 references indexed in Scilit:
- Etiologic heterogeneity among non-Hodgkin lymphoma subtypesBlood, 2008
- Infectious aetiology of Hodgkin and non‐Hodgkin lymphomas: a review of the epidemiological evidenceJournal of Internal Medicine, 2008
- Hematopoietic Malignancies Associated with Viral and Alcoholic HepatitisCancer Epidemiology, Biomarkers & Prevention, 2008
- Trends in Organ Donation and Transplantation in the United States, 1997–2006American Journal of Transplantation, 2008
- Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipientsBlood, 2007
- Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern EuropeEuropean Journal of Cancer, 2007
- Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)Blood, 2007
- Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDSBlood, 2006
- De novo cancers and post‐transplant lymphoproliferative disorder in adult liver transplantationPathology International, 2006
- Primary Central Nervous System Posttransplant Lymphoproliferative DisordersAmerican Journal of Clinical Pathology, 2004